CYGB and Other metabolic disease: In this real-world study, liver function, kidney, muscle and heart biomarkers, including Cre, AST, LDH and CK activities and WBC and HGB levels, were reduced during nab-paclitaxel treatment, suggesting that nab-paclitaxel use may be associated with an increased risk of metabolic disorders.